U.S. FDA Accepts Investigational New Drug (IND) Application for LAE118
January 14, 2026
Source: drugdu
33
China Securities Intelligent Finance: Laekna, Inc. (02105.HK) announced on the morning of January 14 that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for LAE118, a novel pan-mutation selective PI3Kα inhibitor. The drug is intended for the treatment of patients with PIK3CA-mutated solid tumors.
The company stated it will collaborate closely with regulatory authorities to advance the application and is committed to providing this precision therapy to cancer patients in need of new treatment options. LAE118 is a key candidate that the company is actively progressing into clinical research.
https://finance.eastmoney.com/a/202601143618541346.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- First Dry Powder Inhaler from a Chinese Pharmaceutical Company Approved by FDA for U.S. Marketing January 14, 2026
- Sino Biopharmaceutical Acquires Hangzhou Hygieia Biomedical January 14, 2026
- Another boost to domestically developed vaccines! Baihui Biotechnology’s human diploid cell rabies vaccine approved for clinical trials January 14, 2026
- Eli Lilly’s oral weight loss drug has been submitted for marketing approval in China January 14, 2026
- Isaconazole sulfate API approved for market launch, expanding into the antifungal drug field January 14, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
